Ad
related to: diabetic tussin manufacturer listebay.com has been visited by 1M+ users in the past month
Search results
Results from the WOW.Com Content Network
Guaifenesin/codeine is a fixed-dose combination cold medicine used for the treatment of cough. [1] It contains guaifenesin, an expectorant; and codeine, as the phosphate, an opioid antitussive. [1]
It should only contain pages that are Diabetes-related supplies and medical equipment or lists of Diabetes-related supplies and medical equipment, as well as subcategories containing those things (themselves set categories). Topics about Diabetes-related supplies and medical equipment in general should be placed in relevant topic categories.
Cold medicines are a group of medications taken individually or in combination as a treatment for the symptoms of the common cold and similar conditions of the upper respiratory tract.
Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. [3] [4] In 2006, Dexcom received U.S. Food and Drug Administration (FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical founded in 1987 that was based in San Diego, California.The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases.
Guaifenesin might act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi via stimulation of the gastric mucosa. . This stimulation leads to an increased parasympathetic activity in the respiratory tract via the so-called gastro-pulmonary reflex, although some in vitro studies suggested that it might also act directly on the ...
Monitoring was carried out while the pigs were initially non-diabetic and continued for 6 months after the pigs had been made diabetic by administration of a laboratory drug. [5] The long-term animal results reported by David Gough provide a foundation for human trials, which began in January 2015 and are expected to conclude in early 2016.
LifeScan was established in 1981. [3] It was acquired by Johnson & Johnson (J&J) in 1986, [2] [4] and in June 2018, J&J agreed to sell LifeScan to Platinum Equity as part of its strategic exit from the diabetes device market, accepting an offer originally tendered in March 2018. [1]
Ad
related to: diabetic tussin manufacturer listebay.com has been visited by 1M+ users in the past month